Please provide your email address to receive an email when new articles are posted on . Have you had anybody who is actually taking a “generic Restasis”? No? Me either. We’ve certainly gotten all ...

Amneal Pharmaceuticals recently received U.S. FDA approvals for its generic versions of RESTASIS® (cyclosporine ophthalmic emulsion 0.05%) and PROAIR® HFA (albuterol sulfate inhalation aerosol 90 mcg) ...

Allergan plc’s AGN shares declined almost 1% presumably due to the U.S. Supreme Court’s unfavorable ruling in a litigation related to patents covering its blockbuster eye drug, Restasis per an article ...

Allergan faced intense criticism over its attempt to protect Restasis patents through sovereign immunity, and now an appeals court has ruled the strategy won't fly. The U.S. Court of Appeals for the ...

Please provide your email address to receive an email when new articles are posted on . They said it would never happen. We would never see it in our lifetimes. It was a dream held by millions, but ...

Credit: Getty Images. Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated ...

Allergan, a multibillion-dollar drug corporation, is attempting to perpetrate a fraud on the American people that would make Bernie Madoff blush — even as it casts itself as a victim. Allergan makes ...

On Wednesday, the U.S. Food and Drug Administration announced approval to Mylan Pharmaceuticals for a generic form of Allergan's RESTASIS® (Cyclosporine Ophthalmic Emulsion 0.05%) product for ...

Judge Bryson wants AGN to prove the Mohawks should be party to the federal patent litigation. I believe there is a risk lawmakers could abrogate the Mohawks' sovereign immunity pursuant to the case.

The Food and Drug Administration has approved Mylan’s generic Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use vials (eye drops) to increase tear production in patients whose tear ...